Published on November 10, 2017
What are the concerns of using hydroxyurea versus interferon in MPN treatment? Should you take a watch-and-wait approach with low-risk essential thrombocythemia? Andrew Schorr sits down with MPN world-renowned MPN expert Dr. Richard Silver of Weill Cornell Medicine at the Conference of Cancer Research and Treatment Fund’s Annual Conference for MPN Patients in New York City. Watch as Dr. Silver shares information about JAK2 inhibitors, genetic testing and leading-edge transplant news.